Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at Guggenheim

Neumora Therapeutics (NASDAQ:NMRA)‘s stock had its “buy” rating reiterated by investment analysts at Guggenheim in a research report issued on Tuesday,Benzinga reports. They currently have a $14.00 price target on the stock.

A number of other analysts have also issued reports on the company. William Blair upgraded Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Neumora Therapeutics in a research note on Tuesday. Mizuho set a $6.00 price target on Neumora Therapeutics in a research note on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a report on Thursday, January 22nd. Finally, Leerink Partners started coverage on Neumora Therapeutics in a report on Monday, January 12th. They set an “outperform” rating and a $8.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Neumora Therapeutics presently has an average rating of “Hold” and an average target price of $6.71.

Neumora Therapeutics Price Performance

Shares of NMRA opened at $1.99 on Tuesday. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $3.65. The firm’s 50-day simple moving average is $2.73 and its two-hundred day simple moving average is $2.32. The stock has a market cap of $331.84 million, a PE ratio of -1.36 and a beta of 2.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Paul L. Berns sold 9,819 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the sale, the insider owned 7,395,185 shares in the company, valued at $25,957,099.35. This trade represents a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 23,387 shares of company stock valued at $82,647. 26.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of NMRA. Legacy Private Trust Co. purchased a new position in shares of Neumora Therapeutics in the 3rd quarter worth about $25,000. Hsbc Holdings PLC purchased a new position in Neumora Therapeutics in the fourth quarter valued at about $27,000. Virtu Financial LLC purchased a new position in shares of Neumora Therapeutics during the 3rd quarter valued at approximately $31,000. Fred Alger Management LLC acquired a new position in Neumora Therapeutics during the 4th quarter worth $40,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Neumora Therapeutics during the second quarter worth $41,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Key Headlines Impacting Neumora Therapeutics

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: Needham & Company reaffirmed a “buy” rating and set an $8.00 price target — a large upside compared with the current price, which may support bullish sentiment. Benzinga
• Positive Sentiment: Company press release highlights new NMRA-511 data showing a strong clinical signal in a pre-specified subgroup (compared favorably to Rexulti/Auvelity pivotal studies) — this advances the Alzheimer’s agitation program narrative. Press Release
• Positive Sentiment: Unusually large call-option activity (≈2,812 calls) signals speculative bullish interest or hedging by traders, which can amplify intraday moves and volatility.
• Neutral Sentiment: Q4 2025 results and the earnings call emphasized a solid financial position and business update, helping underwrite near-term runway despite operating losses. Earnings Highlights
• Neutral Sentiment: NMRA reported ($0.35) EPS for Q4, missing estimates by $0.01 — a small miss but notable given funding and development timelines. MarketBeat
• Negative Sentiment: Analyst downgrade commentary after KOASTAL-1 (navacaprant) failed its MDD primary endpoint has increased skepticism about the depression program’s prospects; KOASTAL-2/3 remain ongoing but outcomes are uncertain. Seeking Alpha
• Negative Sentiment: Company disclosed a Nasdaq delisting risk that could hurt liquidity, share price, and access to capital — a material risk that likely pressured sentiment and raises fundraising concerns. TipRanks

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.